GHK-Cu and perimenopause skin claims: what the evidence actually supports

A recent TikTok video from ChristineM Wellness addresses women over 40 who experience fatigue, skin changes, gut issues, and metabolic shifts. The creator suggests these symptoms are part of perimenopause and that peptides—short amino acid chains—can help by improving cellular communication. The video highlights GHK-Cu for skin and hair, KPV for inflammation, BPC-157 for gut and joint repair, NAD+ for energy, and retatrutide for metabolic health. While the framing is careful to say “researched for,” the overall impression is that these peptides are broadly beneficial for perimenopause-related concerns. This article examines what the research actually covers for each named compound.

What the research neighborhood covers

GHK-Cu is one of the most studied copper peptides. Its role in skin health is supported by multiple in vitro and ex vivo studies showing it can stimulate collagen production, support wound healing, and exhibit antioxidant properties. However, most clinical evidence is limited to topical applications or small pilot studies, not systemic use for age-related skin changes. The claim that GHK-Cu addresses “skin quality changes that come with estrogen decline” is an extrapolation—no direct clinical trial has tested GHK-Cu against perimenopausal skin aging.

KPV is a tripeptide derived from alpha-melanocyte-stimulating hormone. Its anti-inflammatory effects have been demonstrated in animal models of colitis and other inflammatory conditions. The gut-specific research is promising, but human data are scarce. The video’s suggestion that KPV can reduce “chronic inflammation during perimenopause” is not directly supported by clinical evidence.

BPC-157 is a synthetic peptide studied for accelerating healing of tendons, ligaments, and gastrointestinal ulcers. Animal studies show it can promote angiogenesis and modulate inflammatory pathways. However, no high-quality human trials have confirmed its efficacy for gut integrity or joint repair in perimenopausal women. The link to hormone balance is speculative.

NAD+ is a coenzyme central to cellular respiration. Research on NAD+ precursors (like NMN and NR) has shown they can raise NAD+ levels in humans and may improve some markers of aging, but results are mixed. The claim that NAD+ directly alleviates brain fog or fatigue in midlife women is not established by robust clinical data.

Retatrutide is a GLP-1/GIP/glucagon receptor agonist in clinical trials for obesity and type 2 diabetes. While it affects appetite and metabolism, its role in perimenopause-specific metabolic flexibility is unstudied.

Limits and missing context

A 15-second clip cannot convey the nuance of peptide research. Most studies are preclinical or small-scale. Doses, routes of administration, and long-term safety data are often lacking. The video also omits that many of these peptides are not approved for human use by regulatory agencies—they are research compounds. The phrase “researched for” is accurate but does not mean “proven for.”

Mapping to catalog compounds

For researchers exploring these areas, the catalog includes GHK-Cu, KPV, BPC-157, NAD+, and retatrutide. These are offered for research use only. The catalog also carries related compounds like BPC-157 + TB-500 blend, CJC-1295, Ipamorelin, and others that target similar pathways (e.g., growth hormone secretagogues for metabolic health). However, the specific claims in the video about perimenopause are not directly supported by the literature for any of these peptides.

Research-use caveat

All peptides mentioned are intended for laboratory research and in vitro studies only. They are not approved for human consumption or clinical use. Researchers should consult primary literature and follow institutional guidelines when designing experiments.

Open the full video fact-check page (transcript, takeaways, embedded clip).